<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>IL-6 is a known downstream target of IL-1β and is consistently increased in serum from patients with NLRP3 inflammasome-mediated conditions </plain></SENT>
<SENT sid="1" pm="."><plain>Therefore, IL-6 could be a therapeutic target in the treatment of IL-1β-provoked <z:mp ids='MP_0001845'>inflammation</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>IL-6 was increased in serum with accompanying <z:mp ids='MP_0000219'>neutrophilia</z:mp> in tissues of an inducible mouse model of <z:e sem="disease" ids="C0268390" disease_type="Disease or Syndrome" abbrv="">Muckle-Wells syndrome</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>However, an IL-6-null background failed to provide phenotypic rescue and did not significantly impact inflammatory cytokine levels </plain></SENT>
<SENT sid="4" pm="."><plain>In a second model of IL-1β-driven <z:mp ids='MP_0001845'>inflammation</z:mp>, NLRP3 activation by monosodium urate crystals similarly increased IL-6 </plain></SENT>
<SENT sid="5" pm="."><plain>Consistent with our <z:e sem="disease" ids="C0268390" disease_type="Disease or Syndrome" abbrv="">Muckle-Wells syndrome</z:e> model, ablation of IL-6 did not impact an <z:hpo ids='HP_0011009'>acute</z:hpo> neutrophilic response in this in vivo evaluation of <z:hpo ids='HP_0001997'>gouty arthritis</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Taken together, our results indicate that IL-6 is a reliable marker of <z:mp ids='MP_0001845'>inflammation</z:mp>, with no direct role in inflammasome-mediated disease </plain></SENT>
</text></document>